Redox balance dynamically regulates vascular growth and remodeling

Seminars in Cell and Developmental Biology

Volumn 23, Issue 7, 2012, Pages 745-757

  Bir, Shyamal C ^a   Kolluru, Gopi K ^a   Fang, Kai ^a   Kevil, Christopher G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiogenesis; Antioxidant; Hydrogen peroxide; Nitric oxide; Superoxide

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXIREDOXIN; PHOSPHATASE; PHOSPHOLIPASE C; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THIOREDOXIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CELL ACTIVATION; CELL GROWTH; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; MEDIATOR; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION;

EID: 84866634415     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.05.003     Document Type: Review

References (189)

1. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circulation Research 2005, 97:1093-1107.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995, 1:27-31.
3. Babior B.M. NADPH oxidase. Current Opinion in Immunology 2004, 16:42-47.
4. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxidants & Redox Signaling 2007, 9:731-739.
5. Jones S.A., O'Donnell V.B., Wood J.D., Broughton J.P., Hughes E.J., Jones O.T. Expression of phagocyte NADPH oxidase components in human endothelial cells. American Journal of Physiology 1996, 271:H1626-H1634.
6. Ambasta R.K., Kumar P., Griendling K.K., Schmidt H.H., Busse R., Brandes R.P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. The Journal of Biological Chemistry 2004, 279:45935-45941.
7. Dinauer M.C., Pierce E.A., Bruns G.A., Curnutte J.T., Orkin S.H. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. Journal of Clinical Investigation 1990, 86:1729-1737.
8. Koga H., Terasawa H., Nunoi H., Takeshige K., Inagaki F., Sumimoto H. Tetratricopeptide repeat (TPR) motifs of p67(phox) participate in interaction with the small GTPase Rac and activation of the phagocyte NADPH oxidase. The Journal of Biological Chemistry 1999, 274:25051-25060.
9. Gianni D., DerMardirossian C., Bokoch G.M. Direct interaction between Tks proteins and the N-terminal proline-rich region (PRR) of NoxA1 mediates Nox1-dependent ROS generation. European Journal of Cell Biology 2011, 90:164-171.
10. Martyn K.D., Frederick L.M., von Loehneysen K., Dinauer M.C., Knaus U.G. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cellular Signalling 2006, 18:69-82.
11. Lambeth J.D., Kawahara T., Diebold B. Regulation of Nox and Duox enzymatic activity and expression. Free Radical Biology & Medicine 2007, 43:319-331.
12. Ago T., Kitazono T., Ooboshi H., Iyama T., Han Y.H., Takada J., et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004, 109:227-233.
13. Van Buul J.D., Fernandez-Borja M., Anthony E.C., Hordijk P.L. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxidants & Redox Signaling 2005, 7:308-317.
14. Montezano A.C., Touyz R.M. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic & Clinical Pharmacology & Toxicology 2012, 110:87-94.
15. Inoguchi T., Sonta T., Tsubouchi H., Etoh T., Kakimoto M., Sonoda N., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. Journal of the American Society of Nephrology 2003, 14:S227-S232.
16. von Lohneysen K., Noack D., Wood M.R., Friedman J.S., Knaus U.G. Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. Molecular and Cellular Biology 2010, 30:961-975.
17. Schulz E., Munzel T. NOX5, a new radical player in human atherosclerosis. Journal of the American College of Cardiology 2008, 52:1810-1812.
18. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews 2007, 87:245-313.
19. Fernandes D.C., Manoel A.H., Wosniak J., Laurindo F.R. Protein disulfide isomerase overexpression in vascular smooth muscle cells induces spontaneous preemptive NADPH oxidase activation and Nox1 mRNA expression: effects of nitrosothiol exposure. Archives of Biochemistry and Biophysics 2009, 484:197-204.
20. Li J.M., Shah A.M. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. The Journal of Biological Chemistry 2002, 277:19952-19960.
21. Chen J.X., Zeng H., Tuo Q.H., Yu H., Meyrick B., Aschner J.L. NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. American Journal of Physiology - Heart and Circulatory Physiology 2007, 292:H1664-H1674.
22. Xia C., Meng Q., Liu L.Z., Rojanasakul Y., Wang X.R., Jiang B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Research 2007, 67:10823-10830.
23. Kim Y.M., Kim K.E., Koh G.Y., Ho Y.S., Lee K.J. Hydrogen peroxide produced by angiopoietin-1 mediates angiogenesis. Cancer Research 2006, 66:6167-6174.
24. Zhang D.X., Gutterman D.D. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology 2007, 292:H2023-H2031.
25. Hobbs A.J., Fukuto J.M., Ignarro L.J. Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10992-10996.
26. Radomski M.W., Palmer R.M., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:10043-10047.
27. Schini V.B., Busse R., Vanhoutte P.M. Inducible nitric oxide synthase in vascular smooth muscle. Arzneimittel-Forschung 1994, 44:432-435.
28. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90:649-652.
29. Kuhlmann C.R., Schaefer C.A., Reinhold L., Tillmanns H., Erdogan A. Signalling mechanisms of SDF-induced endothelial cell proliferation and migration. Biochemical and Biophysical Research Communications 2005, 335:1107-1114.
30. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. The American Journal of Pathology 1999, 154:1125-1135.
31. Cooke J.P. NO and angiogenesis. Atherosclerosis. Supplements 2003, 4:53-60.
32. Murohara T., Asahara T., Silver M., Bauters C., Masuda H., Kalka C., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. Journal of Clinical Investigation 1998, 101:2567-2578.
33. Lee P.C., Salyapongse A.N., Bragdon G.A., Shears L.L., Watkins S.C., Edington H.D., et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. American Journal of Physiology 1999, 277:H1600-H1608.
34. Dai X., Faber J.E. Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and impairs activation of a cell cycle gene network during arteriogenesis. Circulation Research 2010, 106:1870-1881.
35. Yu J., deMuinck E.D., Zhuang Z., Drinane M., Kauser K., Rubanyi G.M., et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:10999-11004.
36. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
37. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation 2003, 111:1201-1209.
38. Harrison R. Structure and function of xanthine oxidoreductase: where are we now?. Free Radical Biology & Medicine 2002, 33:774-797.
39. Stipek S., Novak L., Crkovska J., Zima T., Platenik J. Xanthine oxidoreductase. Biochemical, biological and pathogenic functions. Sbornik Lekarsky 1994, 95:289-295.
40. Garattini E., Mendel R., Romao M.J., Wright R., Terao M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochemical Journal 2003, 372:15-32.
41. Kou B., Ni J., Vatish M., Singer D.R. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis. Microcirculation 2008, 15:251-267.
42. McNally J.S., Davis M.E., Giddens D.P., Saha A., Hwang J., Dikalov S., et al. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. American Journal of Physiology - Heart and Circulatory Physiology 2003, 285:H2290-H2297.
43. Berry C., Hamilton C.A., Brosnan M.J., Magill F.G., Berg G.A., McMurray J.J., et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000, 101:2206-2212.
44. Kelley E.E., Khoo N.K., Hundley N.J., Malik U.Z., Freeman B.A., Tarpey M.M. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radical Biology & Medicine 2010, 48:493-498.
45. Ushio-Fukai M., Tang Y., Fukai T., Dikalov S.I., Ma Y., Fujimoto M., et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circulation Research 2002, 91:1160-1167.
46. 2 in rat heart endothelial cells. Free Radical Biology & Medicine 1998, 25:891-897.
47. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916.
48. Bir S.C., Esaki J., Marui A., Yamahara K., Tsubota H., Ikeda T., et al. Angiogenic properties of sustained release platelet-rich plasma: characterization in vitro and in the ischemic hind limb of the mouse. Journal of Vascular Surgery 2009, 50:870-879. e872.
49. Cao R., Brakenhielm E., Pawliuk R., Wariaro D., Post M.J., Wahlberg E., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nature Medicine 2003, 9:604-613.
50. Herbert S.P., Stainier D.Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nature Reviews Molecular Cell Biology 2011, 12:551-564.
51. Luczak K., Balcerczyk A., Soszynski M., Bartosz G. Low concentration of oxidant and nitric oxide donors stimulate proliferation of human endothelial cells in vitro. Cell Biology International 2004, 28:483-486.
52. Ruiz-Gines J.A., Lopez-Ongil S., Gonzalez-Rubio M., Gonzalez-Santiago L., Rodriguez-Puyol M., Rodriguez-Puyol D. Reactive oxygen species induce proliferation of bovine aortic endothelial cells. Journal of Cardiovascular Pharmacology 2000, 35:109-113.
53. Stone J.R., Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002, 9:231-238.
54. Coso S., Harrison I., Harrison C.B., Vinh A., Sobey C., Drummond G.R., et al. Nadph oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxidants & Redox Signaling 2012, 16:1229-1247.
55. Yasuda M., Ohzeki Y., Shimizu S., Naito S., Ohtsuru A., Yamamoto T., et al. Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Life Sciences 1999, 64:249-258.
56. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovascular Research 2006, 71:226-235.
57. Ushio-Fukai M., Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Letters 2008, 266:37-52.
58. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 1999, 13:9-22.
59. Pani G., Colavitti R., Borrello S., Galeotti T. Endogenous oxygen radicals modulate protein tyrosine phosphorylation and JNK-1 activation in lectin-stimulated thymocytes. Biochemical Journal 2000, 347(Pt 1):173-181.
60. Koolwijk P., Peters E., van der Vecht B., Hornig C., Weich H.A., Alitalo K., et al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 2001, 4:53-60.
61. D'Angelo G., Struman I., Martial J., Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:6374-6378.
62. Guo D., Jia Q., Song H.Y., Warren R.S., Donner D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains Association with endothelial cell proliferation. The Journal of Biological Chemistry 1995, 270:6729-6733.
63. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of Biological Chemistry 1997, 272:32521-32527.
64. Xia P., Aiello L.P., Ishii H., Jiang Z.Y., Park D.J., Robinson G.S., et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. Journal of Clinical Investigation 1996, 98:2018-2026.
65. Maraldi T., Prata C., Caliceti C., Vieceli Dalla Sega F., Zambonin L., Fiorentini D., et al. VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis. International Journal of Oncology 2010, 36:1581-1589.
66. Ushio-Fukai M., Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Molecular and Cellular Biochemistry 2004, 264:85-97.
67. Harfouche R., Malak N.A., Brandes R.P., Karsan A., Irani K., Hussain S.N. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB Journal 2005, 19:1728-1730.
68. Garrido-Urbani S., Jemelin S., Deffert C., Carnesecchi S., Basset O., Szyndralewiez C., et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 2011, 6:e14665.
69. Craige S.M., Chen K., Pei Y., Li C., Huang X., Chen C., et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011, 124:731-740.
70. Colavitti R., Pani G., Bedogni B., Anzevino R., Borrello S., Waltenberger J., et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. The Journal of Biological Chemistry 2002, 277:3101-3108.
71. Zhuang J., Jiang T., Lu D., Luo Y., Zheng C., Feng J., et al. NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction. Free Radical Biology & Medicine 2010, 49:227-236.
72. Peshavariya H., Dusting G.J., Jiang F., Halmos L.R., Sobey C.G., Drummond G.R., et al. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn-Schmiedebergs Archives of Pharmacology 2009, 380:193-204.
73. Meng T.C., Fukada T., Tonks N.K. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Molecular Cell 2002, 9:387-399.
74. Boivin B., Zhang S., Arbiser J.L., Zhang Z.Y., Tonks N.K. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9959-9964.
75. Boivin B., Yang M., Tonks N.K. Targeting the reversibly oxidized protein tyrosine phosphatase superfamily. Science Signaling 2010, 3:pl2.
76. Salmeen A., Barford D. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxidants & Redox Signaling 2005, 7:560-577.
77. Chen Y.Y., Chu H.M., Pan K.T., Teng C.H., Wang D.L., Wang A.H., et al. Cysteine S-nitrosylation protects protein-tyrosine phosphatase 1B against oxidation-induced permanent inactivation. The Journal of Biological Chemistry 2008, 283:35265-35272.
78. Zhang J., Somani A.K., Siminovitch K.A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology 2000, 12:361-378.
79. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
80. Tao Q., Spring S.C., Terman B.I. Comparison of the signaling mechanisms by which VEGF, H2O2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase. Microvascular Research 2005, 69:36-44.
81. Thomas S.R., Witting P.K., Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxidants & Redox Signaling 2008, 10:1713-1765.
82. Gopalakrishna R., Chen Z.H., Gundimeda U. Modifications of cysteine-rich regions in protein kinase C induced by oxidant tumor promoters and enzyme-specific inhibitors. Methods in Enzymology 1995, 252:132-146.
83. 2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:6758-6762.
84. Kaul N., Gopalakrishna R., Gundimeda U., Choi J., Forman H.J. Role of protein kinase C in basal and hydrogen peroxide-stimulated NF-kappa B activation in the murine macrophage J774A.1 cell line. Archives of Biochemistry and Biophysics 1998, 350:79-86.
85. Kevil C.G., Ohno N., Gute D.C., Okayama N., Robinson S.A., Chaney E., et al. Role of cadherin internalization in hydrogen peroxide-mediated endothelial permeability. Free Radical Biology & Medicine 1998, 24:1015-1022.
86. Taher M.M., Garcia J.G., Natarajan V. Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Archives of Biochemistry and Biophysics 1993, 303:260-266.
87. Siflinger-Birnboim A., Goligorsky M.S., Del Vecchio P.J., Malik A.B. Activation of protein kinase C pathway contributes to hydrogen peroxide-induced increase in endothelial permeability. Laboratory Investigation 1992, 67:24-30.
88. 2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway. European Journal of Cell Biology 2005, 84:687-697.
89. 2-induced increase in endothelial permeability. American Journal of Physiology 1996, 270:L973-L978.
90. McQuaid K.E., Smyth E.M., Keenan A.K. Evidence for modulation of hydrogen peroxide-induced endothelial barrier dysfunction by nitric oxide in vitro. European Journal of Pharmacology 1996, 307:233-241.
91. Jones M.K., Tsugawa K., Tarnawski A.S., Baatar D. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochemical and Biophysical Research Communications 2004, 318:520-528.
92. Shizukuda Y., Tang S., Yokota R., Ware J.A. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circulation Research 1999, 85:247-256.
93. Farias-Eisner R., Chaudhuri G., Aeberhard E., Fukuto J.M. The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. The Journal of Biological Chemistry 1996, 271:6144-6151.
94. Okayama N., Kevil C.G., Correia L., Jourd'heuil D., Itoh M., Grisham M.B., et al. Nitric oxide enhances hydrogen peroxide-mediated endothelial permeability in vitro. American Journal of Physiology 1997, 273:C1581-C1587.
95. 2 reaction. Chemical Research in Toxicology 1993, 6:23-27.
96. Chandra S., Romero M.J., Shatanawi A., Alkilany A.M., Caldwell R.B., Caldwell R.W. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. British Journal of Pharmacology 2012, 165:506-519.
97. Vepa S., Scribner W.M., Natarajan V. Activation of protein phosphorylation by oxidants in vascular endothelial cells: identification of tyrosine phosphorylation of caveolin. Free Radical Biology & Medicine 1997, 22:25-35.
98. Kevil C.G., Okayama N., Alexander J.S. H(2)O(2)-mediated permeability II: importance of tyrosine phosphatase and kinase activity. American Journal of Physiology-Cell Physiology 2001, 281:C1940-C1947.
99. Lee Y.J., Kang I.J., Bunger R., Kang Y.H. Enhanced survival effect of pyruvate correlates MAPK and NF-kappaB activation in hydrogen peroxide-treated human endothelial cells. Journal of Applied Physiology 2004, 96:793-801. [discussion 792].
100. Chen J.X., Zeng H., Lawrence M.L., Blackwell T.S., Meyrick B. Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. American Journal of Physiology - Heart and Circulatory Physiology 2006, 291:H1563-H1572.
101. 2 prosurvival effects in cultured endothelial cells. FASEB Journal 2006, 20:1501-1503.
102. Monteiro H.P., Arai R.J., Travassos L.R. Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling. Antioxidants & Redox Signaling 2008, 10:843-889.
103. Oliveira C.J., Schindler F., Ventura A.M., Morais M.S., Arai R.J., Debbas V., et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radical Biology & Medicine 2003, 35:381-396.
104. Ridnour L.A., Isenberg J.S., Espey M.G., Thomas D.D., Roberts D.D., Wink D.A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:13147-13152.
105. Rousseau S., Houle F., Landry J., Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997, 15:2169-2177.
106. Huot J., Houle F., Marceau F., Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circulation Research 1997, 80:383-392.
107. 2-induced apoptosis in endothelial cells. Biochemical and Biophysical Research Communications 2008, 368:852-857.
108. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 1996, 16:4604-4613.
109. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. The Journal of Biological Chemistry 1996, 271:17771-17778.
110. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in Molecular Medicine 2002, 8:S62-S67.
111. Li F., Sonveaux P., Rabbani Z.N., Liu S., Yan B., Huang Q., et al. Regulation of HIF-1alpha stability through S-nitrosylation. Molecular Cell 2007, 26:63-74.
112. Lima B., Lam G.K., Xie L., Diesen D.L., Villamizar N., Nienaber J., et al. Endogenous S-nitrosothiols protect against myocardial injury. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:6297-6302.
113. Sumbayev V.V., Budde A., Zhou J., Brune B. HIF-1 alpha protein as a target for S-nitrosation. FEBS Letters 2003, 535:106-112.
114. BelAiba R.S., Djordjevic T., Bonello S., Flugel D., Hess J., Kietzmann T., et al. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biological Chemistry 2004, 385:249-257.
115. Kietzmann T., Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Seminars in Cell & Developmental Biology 2005, 16:474-486.
116. Gorlach A., Berchner-Pfannschmidt U., Wotzlaw C., Cool R.H., Fandrey J., Acker H., et al. Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Thrombosis and Haemostasis 2003, 89:926-935.
117. Deudero J.J., Caramelo C., Castellanos M.C., Neria F., Fernandez-Sanchez R., Calabia O., et al. Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. The Journal of Biological Chemistry 2008, 283:11435-11444.
118. Ni W., Zhan Y., He H., Maynard E., Balschi J.A., Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circulation Research 2007, 101:985-994.
119. Katsume A., Okigaki M., Matsui A., Che J., Adachi Y., Kishita E., et al. Early inflammatory reactions in atherosclerosis are induced by proline-rich tyrosine kinase/reactive oxygen species-mediated release of tumor necrosis factor-alpha and subsequent activation of the p21Cip1/Ets-1/p300 system. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:1084-1092.
120. Arbiser J.L., Petros J., Klafter R., Govindajaran B., McLaughlin E.R., Brown L.F., et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:715-720.
121. Yoon S.O., Park S.J., Yun C.H., Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. Journal of Biochemistry and Molecular Biology 2003, 36:128-137.
122. Csiszar A., Smith K.E., Koller A., Kaley G., Edwards J.G., Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005, 111:2364-2372.
123. Shono T., Ono M., Izumi H., Jimi S.I., Matsushima K., Okamoto T., et al. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Molecular and Cellular Biology 1996, 16:4231-4239.
124. Bonnard C., Durand A., Peyrol S., Chanseaume E., Chauvin M.A., Morio B., et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. Journal of Clinical Investigation 2008, 118:789-800.
125. Inoguchi T., Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Current Drug Targets 2005, 6:495-501.
126. Lee H.S., Son S.M., Kim Y.K., Hong K.W., Kim C.D. NAD(P)H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells. Life Sciences 2003, 72:2719-2730.
127. Zhang Y., Shi H., Sun G., Li S., Xu X., Ye C., et al. High glucose induces dysfunction and apoptosis in endothelial cells: is the effect of high glucose persistence more important than concentration?. Experimental and Clinical Endocrinology & Diabetes 2011, 119:225-233.
128. Alexander R.W. Theodore cooper memorial lecture hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995, 25:155-161.
129. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
130. Rask-Madsen C., King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nature Clinical Practice Endocrinology & Metabolism 2007, 3:46-56.
131. Bravard A., Bonnard C., Durand A., Chauvin M.A., Favier R., Vidal H., et al. Inhibition of xanthine oxidase reduces hyperglycemia-induced oxidative stress and improves mitochondrial alterations in skeletal muscle of diabetic mice. American Journal of Physiology - Endocrinology And Metabolism 2011, 300:E581-E591.
132. Rivard A., Silver M., Chen D., Kearney M., Magner M., Annex B., et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. American Journal of Pathology 1999, 154:355-363.
133. Tamarat R., Silvestre J.S., Huijberts M., Benessiano J., Ebrahimian T.G., Duriez M., et al. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8555-8560.
134. Waltenberger J., Lange J., Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000, 102:185-190.
135. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
136. Ebrahimian T.G., Heymes C., You D., Blanc-Brude O., Mees B., Waeckel L., et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. The American Journal of Pathology 2006, 169:719-728.
137. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Medicine 2003, 9:1370-1376.
138. Wohaieb S.A., Godin D.V. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987, 36:1014-1018.
139. Aktunc E., Ozacmak V.H., Ozacmak H.S., Barut F., Buyukates M., Kandemir O., et al. N-acetyl cysteine promotes angiogenesis and clearance of free oxygen radicals, thus improving wound healing in an alloxan-induced diabetic mouse model of incisional wound. Clinical and Experimental Dermatology 2010, 35:902-909.
140. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopathy. Experimental Diabetes Research 2007, 2007:43603.
141. Kowluru R.A., Tang J., Kern T.S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001, 50:1938-1942.
142. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. Journal of Clinical Investigation 1998, 101:1219-1224.
143. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Research 2011, 21:103-115.
144. Carmo A., Cunha-Vaz J.G., Carvalho A.P., Lopes M.C. l-Arginine transport in retinas from streptozotocin diabetic rats: correlation with the level of IL-1 beta and NO synthase activity. Vision Research 1999, 39:3817-3823.
145. Kowluru R.A., Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. British Journal of Ophthalmology 2004, 88:1343-1347.
146. Dijkstra G., Moshage H., van Dullemen H.M., de Jager-Krikken A., Tiebosch A.T., Kleibeuker J.H., et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. Journal of Pathology 1998, 186:416-421.
147. Liu L.Z., Hu X.W., Xia C., He J., Zhou Q., Shi X., et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radical Biology & Medicine 2006, 41:1521-1533.
148. Jackson A.L., Loeb L.A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutation Research 2001, 477:7-21.
149. Stevenson M.A., Pollock S.S., Coleman C.N., Calderwood S.K. X-irradiation, phorbol esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates. Cancer Research 1994, 54:12-15.
150. Skinner H.D., Zheng J.Z., Fang J., Agani F., Jiang B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. The Journal of Biological Chemistry 2004, 279:45643-45651.
151. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 209-233.
152. Jung H.J., Shim J.S., Lee J., Song Y.M., Park K.C., Choi S.H., et al. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced reactive oxygen species production and cellular oxygen sensing. The Journal of Biological Chemistry 2010, 285:11584-11595.
153. Jing Y., Liu L.Z., Jiang Y., Zhu Y., Guo N.L., Barnett J., et al. Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicological Sciences 2012, 125:10-19.
154. Maulik N., Das D.K. Redox signaling in vascular angiogenesis. Free Radical Biology & Medicine 2002, 33:1047-1060.
155. Schroedl C., McClintock D.S., Budinger G.R., Chandel N.S. Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. American Journal of Physiology - Lung Cellular and Molecular Physiology 2002, 283:L922-L931.
156. 2 sensing: the search continues. American Journal of Physiology - Lung Cellular and Molecular Physiology 2002, 283:L918-L921.
157. Sauer H., Bekhite M.M., Hescheler J., Wartenberg M. Redox control of angiogenic factors and CD31-positive vessel-like structures in mouse embryonic stem cells after direct current electrical field stimulation. Experimental Cell Research 2005, 304:380-390.
158. Schmelter M., Ateghang B., Helmig S., Wartenberg M., Sauer H. Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation. FASEB Journal 2006, 20:1182-1184.
159. Kuroki M., Voest E.E., Amano S., Beerepoot L.V., Takashima S., Tolentino M., et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. Journal of Clinical Investigation 1996, 98:1667-1675.
160. Tojo T., Ushio-Fukai M., Yamaoka-Tojo M., Ikeda S., Patrushev N., Alexander R.W. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 2005, 111:2347-2355.
161. Nijmeh J., Moldobaeva A., Wagner E.M. Role of ROS in ischemia-induced lung angiogenesis. American Journal of Physiology - Lung Cellular and Molecular Physiology 2010, 299:L535-L541.
162. Judkins C.P., Diep H., Broughton B.R., Mast A.E., Hooker E.U., Miller A.A., et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. American Journal of Physiology - Heart and Circulatory Physiology 2010, 298:H24-H32.
163. Haddad P., Dussault S., Groleau J., Turgeon J., Michaud S.E., Menard C., et al. Nox2-containing NADPH oxidase deficiency confers protection from hindlimb ischemia in conditions of increased oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29:1522-1528.
164. Yamawaki H., Haendeler J., Berk B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circulation Research 2003, 93:1029-1033.
165. Welsh S.J., Bellamy W.T., Briehl M.M., Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Research 2002, 62:5089-5095.
166. Takagi Y., Kikuta K., Moriwaki T., Aoki T., Nozaki K., Hashimoto N., et al. Expression of thioredoxin-1 and hypoxia inducible factor-1alpha in cerebral arteriovenous malformations: possible role of redox regulatory factor in neoangiogenic property. Surgical Neurology International 2011, 2:61.
167. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Koneru S., Zhan L., Maulik G., et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 2010, 121:1244-1255.
168. Adluri R.S., Thirunavukkarasu M., Zhan L., Akita Y., Samuel S.M., Otani H., et al. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. Journal of Molecular and Cellular Cardiology 2011, 50:239-247.
169. Dai S., He Y., Zhang H., Yu L., Wan T., Xu Z., et al. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29:495-502.
170. Dunn L.L., Buckle A.M., Cooke J.P., Ng M.K. The emerging role of the thioredoxin system in angiogenesis. Arteriosclerosis, Thrombosis, And Vascular Biology 2010, 30:2089-2098.
171. Mieyal J.J., Chock P.B. Posttranslational modification of cysteine in redox signaling and oxidative stress: focus on S-glutathionylation. Antioxidants & Redox Signaling 2012, 16:471-475.
172. Zhang H., Forman H.J. Glutathione synthesis and its role in redox signaling. Seminars in Cell & Developmental Biology 2012, [Epub ahead of print]. 10.1016/j.semcdb.2012.03.017.
173. Mallery S.R., Lantry L.E., Laufman H.B., Stephens R.E., Brierley G.P. Modulation of human microvascular endothelial cell bioenergetic status and glutathione levels during proliferative and differentiated growth. Journal of Cellular Biochemistry 1993, 53:360-372.
174. Albini A., Morini M., D'Agostini F., Ferrari N., Campelli F., Arena G., et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Research 2001, 61:8171-8178.
175. Schwartz J.L., Shklar G. Glutathione inhibits experimental oral carcinogenesis, p53 expression, and angiogenesis. Nutrition and Cancer 1996, 26:229-236.
176. Sihvo E.I., Ruohtula T., Auvinen M.I., Koivistoinen A., Harjula A.L., Salo J.A. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. The Journal of Thoracic and Cardiovascular Surgery 2003, 126:1952-1957.
177. Kevil C.G., Pruitt H., Kavanagh T.J., Wilkerson J., Farin F., Moellering D., et al. Regulation of endothelial glutathione by ICAM-1: implications for inflammation. FASEB Journal 2004, 18:1321-1323.
178. Pruitt H.M., Langston W., Kevil C.G., Patel R.P. ICAM-1 cross-linking stimulates endothelial glutathione synthesis. Antioxidants & Redox Signaling 2007, 9:159-164.
179. Langston W., Chidlow J.H., Booth B.A., Barlow S.C., Lefer D.J., Patel R.P., et al. Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radical Biology & Medicine 2007, 42:720-729.
180. Pattillo C.B., Pardue S., Shen X., Fang K., Langston W., Jourd'heuil D., et al. ICAM-1 cytoplasmic tail regulates endothelial glutathione synthesis through a NOX4/PI3-kinase-dependent pathway. Free Radical Biology & Medicine 2010, 49:1119-1128.
181. Tajima M., Kurashima Y., Sugiyama K., Ogura T., Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. European Journal of Pharmacology 2009, 606:45-49.
182. Galasso G., Schiekofer S., Sato K., Shibata R., Handy D.E., Ouchi N., et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circulation Research 2006, 98:254-261.
183. Rhee S.G., Woo H.A. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H(2)O(2), and protein chaperones. Antioxidants & Redox Signaling 2011, 15:781-794.
184. Kisucka J., Chauhan A.K., Patten I.S., Yesilaltay A., Neumann C., Van Etten R.A., et al. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circulation Research 2008, 103:598-605.
185. Park J.G., Yoo J.Y., Jeong S.J., Choi J.H., Lee M.R., Lee M.N., et al. Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. Circulation Research 2011, 109:739-749.
186. Mowbray A.L., Kang D.H., Rhee S.G., Kang S.W., Jo H. Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. The Journal of Biological Chemistry 2008, 283:1622-1627.
187. Riddell J.R., Bshara W., Moser M.T., Spernyak J.A., Foster B.A., Gollnick S.O. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Research 2011, 71:1637-1646.
188. Lee S.C., Na Y.P., Lee J.B. Expression of peroxiredoxin II in vascular tumors of the skin: a novel vascular marker of endothelial cells. Journal of the American Academy of Dermatology 2003, 49:487-491.
189. Kang D.H., Lee D.J., Lee K.W., Park Y.S., Lee J.Y., Lee S.H., et al. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Molecular Cell 2011, 44:545-558.